{"id":1843,"date":"2023-05-09T10:12:52","date_gmt":"2023-05-09T02:12:52","guid":{"rendered":"https:\/\/unionmedin.com\/?p=1843"},"modified":"2023-05-09T10:12:52","modified_gmt":"2023-05-09T02:12:52","slug":"%e7%be%8e%e6%95%a6%e5%8a%9b%e6%9c%80%e6%96%b0%e5%b9%b4%e6%8a%a5%e5%87%ba%e7%82%89","status":"publish","type":"post","link":"https:\/\/unionmedin.com\/?p=1843","title":{"rendered":"\u7f8e\u6566\u529b\u6700\u65b0\u5e74\u62a5\u51fa\u7089"},"content":{"rendered":"
2022\u5e745\u670826\u65e5\uff0c\u7f8e\u6566\u529b\uff08\u7ebd\u7ea6\u8bc1\u5238\u4ea4\u6613\u6240\u4ee3\u7801\uff1aMDT\uff09\u516c\u5e032022\u8d22\u5e74\u5168\u5e74\u548c\u7b2c\u56db\u5b63\u5ea6\u8d22\u62a5\uff08\u7f8e\u6566\u529b2022\u5e74\u8d22\u5e74\u65f6\u95f4\u4e3a\uff1a2021\u5e744\u670825\u65e5\u52302022\u5e744\u670829\u65e5\uff09\u3002<\/section>\n

\n

2022\u8d22\u5e74\u5168\u5e74\u6536\u5165316.86 \u4ebf\u7f8e\u5143\uff082122.5\u4ebf\u4eba\u6c11\u5e01\uff09\uff0c\u6309\u62a5\u544a\u548c\u6709\u673a\u589e\u957f 5%\uff1b<\/section>\n
\u7b2c\u56db\u5b63\u5ea6\u6536\u516580.89\u4ebf\u7f8e\u5143\uff0c\u201c\u53d7\u5168\u7403\u4f9b\u5e94\u94fe\u548c\u4e2d\u56fd\u75ab\u60c5\u7ba1\u63a7\u5f71\u54cd\u201d\uff0c\u4e0b\u964d1%\u3002<\/section>\n


\n<\/section>\n
    \n
  • \n

    \n\t\t\t\u5fc3\u8840\u7ba1\u4ea7\u54c1\u7ec4\u5408\uff1a\u6536\u5165\u4e3a 114.23 \u4ebf\u7f8e\u5143\uff0c\u589e\u957f 6%\n\t\t<\/p>\n<\/li>\n

  • \n

    \n\t\t\t\u533b\u7597\u5916\u79d1\u4ea7\u54c1\u7ec4\u5408\uff1a\u6536\u5165\u4e3a  91.41 \u4ebf\u7f8e\u5143\uff0c\u589e\u957f 5%\n\t\t<\/p>\n<\/li>\n

  • \n

    \n\t\t\t\u795e\u7ecf\u79d1\u5b66\u4ea7\u54c1\u7ec4\u5408\uff1a\u6536\u5165\u4e3a 87.84 \u4ebf\u7f8e\u5143\uff0c\u589e\u957f 7%\n\t\t<\/p>\n<\/li>\n

  • \n

    \n\t\t\t\u7cd6\u5c3f\u75c5\uff1a\u6536\u5165\u4e3a 23.38 \u4ebf\u7f8e\u5143\uff0c\u4e0b\u964d 3%\n\t\t<\/p>\n<\/li>\n<\/ul>\n



    \n<\/section>\n
    \u5168\u5e74\u548c\u7b2c\u56db\u5b63\u5ea6\u60c5\u51b5<\/section>\n
    2022\u8d22\u5e74\u5168\u5e74\u6536\u5165316.86 \u4ebf\u7f8e\u5143\uff082122.5\u4ebf\u4eba\u6c11\u5e01\uff09\uff0c\u6309\u62a5\u544a\u548c\u6709\u673a\u589e\u957f 5%\uff1b2022 \u8d22\u5e74\u8fd0\u8425\u73b0\u91d1\u6d41\u4e3a 73.46 \u4ebf\u7f8e\u5143\uff0c\u589e\u957f 18%\u30022022 \u8d22\u5e7459.78\u4ebf\u7f8e\u5143\u7684\u81ea\u7531\u73b0\u91d1\u6d41\u589e\u957f\u4e86 22%\uff0c\u4ee3\u8868\u4e86 80%\u7684\u975eGAAP \u51c0\u6536\u76ca\u7684\u81ea\u7531\u73b0\u91d1\u6d41\u8f6c\u6362\u3002<\/section>\n
    \u7b2c\u56db\u5b63\u5ea6\u5168\u7403\u6536\u5165\u4e3a80.89 \u4ebf\u7f8e\u5143\uff0c\u62a5\u544a\u4e0b\u964d 1%\uff0c\u6709\u673a\u589e\u957f 1%\uff0c\u5176\u4e2d\u4e0d\u5305\u62ec\u5916\u5e01\u6362\u7b97\u76842.15 \u4ebf\u7f8e\u5143\u8d1f\u9762\u5f71\u54cd\u3002\u7531\u4e8e\u6700\u8fd1\u7684 COVID-19 \u5c01\u9501\uff0c\u8be5\u516c\u53f8\u7b2c\u56db\u5b63\u5ea6\u7684\u6536\u5165\u7ed3\u679c\u53d7\u5230\u4e0e\u5168\u7403\u4f9b\u5e94\u94fe\u76f8\u5173\u7684\u4e34\u65f6\u95ee\u9898\u7684\u5f71\u54cd\uff0c\u7279\u522b\u662f Surgical Innovations\u677f\u5757 \u548c\u4e2d\u56fd\u5730\u533a\u3002\u7b2c\u56db\u5b63\u5ea6 GAAP \u51c0\u5229\u6da6\u548c\u644a\u8584\u540e\u6bcf\u80a1\u6536\u76ca (EPS) \u5206\u522b\u4e3a 14.85 \u4ebf\u7f8e\u5143\u548c1.10 \u7f8e\u5143\uff0c\u5206\u522b\u589e\u957f 9% \u548c 10%\u3002<\/section>\n


    \n<\/section>\n
    \u56db\u5b63\u5ea6\u5730\u533a\u6536\u5165\uff1a<\/section>\n
    \u7b2c\u56db\u5b63\u5ea6\u7f8e\u56fd\u6536\u5165\u4e3a 40.97\u4ebf\u7f8e\u5143\uff0c\u5360\u516c\u53f8\u6536\u5165\u7684 51%\uff0c\u4e0b\u964d 2%\u3002<\/section>\n
    \u975e\u7f8e\u56fd\u53d1\u8fbe\u5e02\u573a\u6536\u5165\u4e3a 26.09\u4ebf\u7f8e\u5143\uff0c\u5360\u516c\u53f8\u6536\u5165\u7684 32%\uff0c\u636e\u62a5\u9053\u4e0b\u964d 2%\uff0c\u6709\u673a\u589e\u957f 4%\u3002<\/section>\n
    \u65b0\u5174\u5e02\u573a\u6536\u5165\u4e3a 13.83 \u4ebf\u7f8e\u5143\uff0c\u5360\u516c\u53f8\u6536\u5165\u7684 17%\uff0c\u636e\u62a5\u9053\u589e\u957f 4%\uff0c\u6709\u673a\u589e\u957f 7%\u3002<\/section>\n


    \n<\/section>\n
    \u7531\u4e8e COVID-19 \u5c01\u9501\uff0c\u4e2d\u56fd\u6536\u5165\uff08\u5360\u65b0\u5174\u5e02\u573a\u6536\u5165\u768443%\uff09\u4e0b\u964d\u4e86 10%\u3002<\/section>\n


    \n<\/section>\n
    \u201c\u5168\u7403\u4f9b\u5e94\u94fe\u548c\u4e2d\u56fd\u7684COVID-19\u63a7\u5236\u5bf9\u6211\u4eec\u7b2c\u56db\u5b63\u5ea6\u7684\u4e1a\u7ee9\u4ea7\u751f\u4e86\u4e25\u91cd\u5f71\u54cd\u3002\u6211\u4eec\u4e86\u89e3\u6839\u672c\u539f\u56e0\uff0c\u6211\u4eec\u6b63\u5728\u89e3\u51b3\u5b83\u4eec\uff0c\u6211\u4eec\u9884\u8ba1\u5b83\u4eec\u5c06\u5728\u77ed\u671f\u5185\u5f97\u5230\u89e3\u51b3\uff0c\u201d\u7f8e\u6566\u529b\u8463\u4e8b\u957f\u517c\u9996\u5e2d\u6267\u884c\u5b98\u6770\u592b\u9a6c\u8428\u8bf4\u3002\u201c\u6211\u4eec\u4ecd\u7136\u4e13\u6ce8\u4e8e\u5728\u5feb\u901f\u589e\u957f\u7684\u5e02\u573a\u4e2d\u901a\u8fc7\u5f3a\u5927\u7684\u6280\u672f\u7ba1\u9053\u5b9e\u73b0\u521b\u65b0\u9a71\u52a8\u7684\u589e\u957f\uff0c\u6211\u4eec\u81f4\u529b\u4e8e\u901a\u8fc7\u6218\u7565\u6027\u8d44\u672c\u5206\u914d\u548c\u79ef\u6781\u7684\u6295\u8d44\u7ec4\u5408\u7ba1\u7406\u6765\u521b\u9020\u5f3a\u5927\u7684\u80a1\u4e1c\u4ef7\u503c\u3002\u201d<\/section>\n

    \n\t\n<\/p>\n

    \u5fc3\u8840\u7ba1\u4ea7\u54c1\u7ec4\u5408\uff1a\u6536\u5165\u4e3a 114.23 \u4ebf\u7f8e\u5143\uff0c\u589e\u957f 6%<\/section>\n
    \u5fc3\u8840\u7ba1\u4ea7\u54c1\u7ec4\u5408\u5305\u62ec\u5fc3\u5f8b\u548c\u5fc3\u529b\u8870\u7aed (CRHF)\u3001\u7ed3\u6784\u6027\u5fc3\u810f\u548c\u4e3b\u52a8\u8109 (SHA) \u4ee5\u53ca\u51a0\u72b6\u52a8\u8109\u548c\u5916\u5468\u8840\u7ba1 (CPV) \u90e8\u95e8\u3002<\/section>\n


    \n<\/section>\n
    \u636e\u62a5\u9053\uff0c 2022 \u8d22\u5e74\u5fc3\u8840\u7ba1\u6536\u5165\u4e3a 114.23 \u4ebf\u7f8e\u5143\uff0c\u589e\u957f 6%\uff0c\u6709\u673a\u589e\u957f 6%\u3002\u7b2c\u56db\u5b63\u5ea6\u5fc3\u8840\u7ba1\u6536\u5165\u4e3a 29.61 \u4ebf\u7f8e\u5143\uff0c\u636e\u62a5\u544a\u589e\u957f 2%\uff0c\u6709\u673a\u589e\u957f 5%\uff0c\u8fd9\u5f97\u76ca\u4e8e SHA \u7684\u9ad8\u4e2a\u4f4d\u6570\u6709\u673a\u589e\u957f\u548c CRM \u548c CPV \u7684\u4e2d\u4e2a\u4f4d\u6570\u6709\u673a\u589e\u957f\u3002<\/section>\n


    \n<\/section>\n
      \n
    • \n

      \n\t\t\t\u5fc3\u5f8b\u5931\u5e38\u548c\u5fc3\u529b\u8870\u7aed\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 15.52 \u4ebf\u7f8e\u5143\u62a5\u544a\u589e\u52a0 1%\uff0c\u6709\u673a\u589e\u52a0 4%\u3002\u8c03\u6574 HVAD\u2122 \u7cfb\u7edf\u9500\u552e\u7684\u7ec8\u6b62\u540e\uff0cCRHF \u6536\u5165\u6709\u673a\u589e\u957f 6%\u3002\u5fc3\u5f8b\u7ba1\u7406\u6536\u5165\u4ee5\u4e2d\u4e2a\u4f4d\u6570\u589e\u957f\uff0c\u9664\u98a4\u89e3\u51b3\u65b9\u6848\u5b9e\u73b0\u4f4e\u4e2a\u4f4d\u6570\u589e\u957f\uff0c\u5fc3\u810f\u8d77\u640f\u6cbb\u7597\u5b9e\u73b0\u9ad8\u4e2a\u4f4d\u6570\u589e\u957f\uff0c\u5305\u62ec\u968f\u7740 Micra\u2122 \u7ecf\u5bfc\u7ba1\u8d77\u640f\u5728\u5168\u7403\u8303\u56f4\u5185\u7684\u6301\u7eed\u91c7\u7528\uff0c\u65e0\u5f15\u7ebf\u8d77\u640f\u5668\u5b9e\u73b0\u4f4e\u4e2a\u4f4d\u6570\u589e\u957f\u7cfb\u7edf\u3002\u7531\u4e8e TYRX\u2122 \u53ef\u5438\u6536\u6297\u83cc\u4fe1\u5c01\u7684\u5f3a\u52b2\u9500\u552e\uff0cProcedure Innovations \u7684\u6536\u5165\u5728 20 \u5e74\u4ee3\u4e2d\u671f\u6709\u6240\u589e\u52a0\u3002\u5fc3\u8840\u7ba1\u8bca\u65ad\u6536\u5165\u589e\u957f\u4e2d\u4e2a\u4f4d\u6570\uff0c\u5fc3\u810f\u6d88\u878d\u89e3\u51b3\u65b9\u6848\u6536\u5165\u589e\u957f\u4e2d\u4e2a\u4f4d\u6570\uff0c\u8fd9\u4e3b\u8981\u5f97\u76ca\u4e8e\u5206\u522b\u91c7\u7528 LINQ II \u2122\u53ef\u63d2\u5165\u5fc3\u810f\u76d1\u62a4\u4eea\u548c Arctic Front Advance \u2122\u51b7\u51bb\u7403\u56ca\u5bfc\u7ba1\u548c\u63a7\u5236\u53f0\u3002\n\t\t<\/p>\n

      \n<\/li>\n

    • \n

      \n\t\t\t\u7ed3\u6784\u6027\u5fc3\u810f\u548c\u4e3b\u52a8\u8109\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 7.78 \u4ebf\u7f8e\u5143\uff0c\u636e\u62a5\u9053\u589e\u957f 5%\uff0c\u6709\u673a\u589e\u957f 8%\u3002\u53d7\u9752\u5c11\u5e74\u7ecf\u5bfc\u7ba1\u4e3b\u52a8\u8109\u74e3 (TAVR) \u589e\u957f\u7684\u63a8\u52a8\uff0c\u7ed3\u6784\u6027\u5fc3\u810f\u5728\u9752\u5c11\u5e74\u4e2d\u671f\u589e\u957f\u3002\u7531\u4e8e\u4f9b\u5e94\u94fe\u548c\u8d28\u91cf\u6311\u6218\u7684\u4ea7\u54c1\u53ef\u7528\u6027\u95ee\u9898\uff0c\u4e3b\u52a8\u8109\u4e0b\u964d\u4e86\u4e2d\u4e2a\u4f4d\u6570\u3002\u5728\u704c\u6ce8\u4e13\u8425\u6743\u5b9e\u529b\u7684\u63a8\u52a8\u4e0b\uff0c\u5fc3\u810f\u5916\u79d1\u624b\u672f\u4ee5\u9ad8\u4e2a\u4f4d\u6570\u589e\u957f\u3002\n\t\t<\/p>\n

      \n<\/li>\n

    • \n

      \n\t\t\tCoronary & Peripheral Vascular\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 6.31 \u4ebf\u7f8e\u5143\uff0c\u636e\u62a5\u9053\u589e\u957f 1%\uff0c\u6709\u673a\u589e\u957f 4%\u3002\u51a0\u72b6\u52a8\u8109\u548c\u80be\u810f\u53bb\u795e\u7ecf\uff08CRDN\uff09\u5728\u4f4e\u4e2a\u4f4d\u6570\u589e\u52a0\uff0c\u5f15\u5bfc\u5bfc\u7ba1\u7684\u9ad8\u9752\u5c11\u5e74\u589e\u957f\u62b5\u6d88\u4e86\u836f\u7269\u6d17\u8131\u652f\u67b6\u7684\u4f4e\u4e2a\u4f4d\u6570\u4e0b\u964d\u3002\u7531\u4e8e VenaSeal\u2122 \u95ed\u5408\u7cfb\u7edf\u548c Abre\u2122 \u6df1\u9759\u8109\u652f\u67b6\u7684\u5f3a\u52b2\u9500\u552e\uff0c20 \u5c81\u4ee5\u4e0b\u7684\u9759\u8109\u5185\u589e\u957f\u63a8\u52a8\u4e86\u5916\u5468\u8840\u7ba1\u5065\u5eb7\u7684\u4e2d\u4e2a\u4f4d\u6570\u589e\u957f\u3002\n\t\t<\/p>\n<\/li>\n<\/ul>\n



      \n<\/section>\n
      \u533b\u7597\u5916\u79d1\u4ea7\u54c1\u7ec4\u5408\uff1a91.41 \u4ebf\u7f8e\u5143\uff0c\u6309\u62a5\u544a\u548c\u6709\u673a\u589e\u957f 5%<\/section>\n
      \u533b\u7597\u5916\u79d1\u4ea7\u54c1\u7ec4\u5408\u5305\u62ec\u5916\u79d1\u521b\u65b0 (SI) \u548c\u547c\u5438\u3001\u80c3\u80a0\u548c\u80be\u810f (RGR) \u90e8\u95e8\u3002<\/section>\n
      \u533b\u7597\u5916\u79d1 2022 \u8d22\u5e74\u6536\u5165\u4e3a 91.41 \u4ebf\u7f8e\u5143\uff0c\u6309\u62a5\u544a\u548c\u6709\u673a\u589e\u957f 5%\u3002\u8003\u8651\u5230\u4e0a\u4e00\u5e74 COVID-19 \u76f8\u5173\u9700\u6c42\u589e\u52a0\uff0c\u6392\u9664\u547c\u5438\u673a\u9500\u552e\u7684\u5f71\u54cd\uff0c2022 \u8d22\u5e74\u6536\u5165\u6709\u673a\u589e\u957f 9%\u3002<\/section>\n


      \n<\/section>\n
      \u533b\u7597\u5916\u79d1\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 22.31 \u4ebf\u7f8e\u5143\uff0c\u636e\u62a5\u544a\u4e0b\u964d 5%\uff0c\u6709\u673a\u4e0b\u964d 1%\uff0cSI \u7684\u6709\u673a\u7ed3\u679c\u540c\u6bd4\u6301\u5e73\u88ab RGR \u7684\u4e2d\u4e2a\u4f4d\u6570\u6709\u673a\u4e0b\u964d\u6240\u62b5\u6d88\u3002\u6392\u9664\u547c\u5438\u673a\u9500\u552e\u7684\u5f71\u54cd\uff0cMedical Surgical \u7b2c\u56db\u5b63\u5ea6\u7684\u6709\u673a\u6536\u5165\u4e0e\u53bb\u5e74\u540c\u671f\u6301\u5e73\u3002<\/section>\n


      \n<\/section>\n
        \n
      • \n

        \n\t\t\t\u636e\u62a5\u9053\uff0c Surgical Innovations\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 14.91\u4ebf\u7f8e\u5143\uff0c\u4e0b\u964d 3%\uff0c\u7531\u4e8e\u67d0\u4e9b\u539f\u6750\u6599\u7684\u4f9b\u5e94\u9650\u5236\uff0c\u6709\u673a\u6536\u5165\u540c\u6bd4\u6301\u5e73\u3002\u6b64\u5916\uff0c\u8be5\u90e8\u95e8\u8fd8\u53d7\u5230\u4e2d\u56fd\u8fd1\u671f COVID-19 \u5c01\u9501\u7684\u5f71\u54cd\uff0c\u5bfc\u81f4\u4e2d\u56fd\u7684 SI \u6536\u5165\u4e0b\u964d\u4e86\u767e\u5206\u4e4b\u5341\u51e0\u3002\u8fd9\u4e9b\u6311\u6218\u5bfc\u81f4 Advanced Surgical Instruments \u5728\u5168\u7403\u8303\u56f4\u5185\u4ee5\u4f4e\u4e2a\u4f4d\u6570\u4e0b\u964d\uff0c\u5305\u62ec Advanced Staples \u7684\u4f4e\u4e2a\u4f4d\u6570\u4e0b\u964d\u548c Advanced Energy \u7684\u4e2d\u4e2a\u4f4d\u6570\u4e0b\u964d\u3002\u8fd9\u88ab\u759d\u6c14\u548c\u4f24\u53e3\u7ba1\u7406\u7684\u9752\u5c11\u5e74\u589e\u957f\u90e8\u5206\u62b5\u6d88\u3002\n\t\t<\/p>\n

        \n<\/li>\n

      • \n

        \n\t\t\t\u547c\u5438\u3001\u80c3\u80a0\u548c\u80be\u810f\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 7.4 \u4ebf\u7f8e\u5143\u636e\u62a5\u9053\uff0c\u4e0b\u964d\u4e86 7%\uff0c\u6709\u673a\u4e0b\u964d\u4e86 4%\u3002\u6392\u9664\u547c\u5438\u673a\u9500\u552e\u7684\u5f71\u54cd\uff0cRGR \u6709\u673a\u6536\u5165\u540c\u6bd4\u6301\u5e73\u3002\u547c\u5438\u5e72\u9884\u5728 10 \u5e74\u4ee3\u4e2d\u671f\u6709\u6240\u4e0b\u964d\uff0c\u968f\u7740\u9700\u6c42\u6062\u590d\u5230\u5927\u6d41\u884c\u524d\u7684\u6c34\u5e73\uff0c\u547c\u5438\u673a\u7684\u9500\u91cf\u5728 30 \u5e74\u4ee3\u4e2d\u671f\u4e0b\u964d\u3002\u60a3\u8005\u76d1\u6d4b\u4ee5\u4e2d\u4e2a\u4f4d\u6570\u589e\u957f\uff0cNellcor \u2122\u8109\u640f\u8840\u6c27\u9971\u548c\u5ea6\u4ea7\u54c1\u548c\u56f4\u624b\u672f\u671f\u5e76\u53d1\u75c7\u4ea7\u54c1\u5747\u5b9e\u73b0\u4e2d\u4e2a\u4f4d\u6570\u589e\u957f\uff0c\u4f46\u88ab Respiratory Compromise \u89e3\u51b3\u65b9\u6848\u7684\u4f4e\u4e24\u4f4d\u6570\u4e0b\u964d\u6240\u62b5\u6d88\u3002\u9274\u4e8e COVID-19 \u5bf9\u624b\u672f\u91cf\u7684\u538b\u529b\uff0c\u80c3\u80a0\u9053\u6536\u5165\u4e0b\u964d\u4e86\u4e2d\u4e2a\u4f4d\u6570\u3002\u80be\u810f\u62a4\u7406\u89e3\u51b3\u65b9\u6848\u4ee5\u4f4e\u4e2a\u4f4d\u6570\u589e\u957f\uff0c\u5305\u62ec\u6025\u6027\u6cbb\u7597\u7684\u9ad8\u4e2a\u4f4d\u6570\u589e\u957f\u3002\n\t\t<\/p>\n<\/li>\n<\/ul>\n



        \n<\/section>\n
        \u795e\u7ecf\u79d1\u5b66\u4ea7\u54c1\u7ec4\u5408\uff1a87.84 \u4ebf\u7f8e\u5143\uff0c\u589e\u957f 7%<\/section>\n
        \u795e\u7ecf\u79d1\u5b66\u4ea7\u54c1\u7ec4\u5408\u5305\u62ec\u9885\u8111\u548c\u810a\u67f1\u6280\u672f (CST)\u3001\u4e13\u4e1a\u6cbb\u7597\u548c\u795e\u7ecf\u8c03\u8282\u90e8\u95e8\u3002<\/section>\n
        \u795e\u7ecf\u79d1\u5b66 2022 \u8d22\u5e74\u7684\u6536\u5165\u4e3a 87.84 \u4ebf\u7f8e\u5143\uff0c\u62a5\u544a\u548c\u6709\u673a\u589e\u957f\u4e86 7%\u3002<\/section>\n
        \u636e\u62a5\u9053\uff0c\u795e\u7ecf\u79d1\u5b66\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a22.99 \u4ebf\u7f8e\u5143\uff0c\u540c\u6bd4\u6301\u5e73\uff0c\u6709\u673a\u589e\u957f 2%\uff0c\u5176\u4e2d\u4e13\u4e1a\u6cbb\u7597\u7684\u4e2d\u4e2a\u4f4d\u6570\u6709\u673a\u589e\u957f\u548c\u795e\u7ecf\u8c03\u8282\u7684\u4f4e\u4e2a\u4f4d\u6570\u6709\u673a\u589e\u957f\u88ab\u4f4e\u4e2a\u4f4d\u6570\u6709\u673a\u4e0b\u964d\u90e8\u5206\u62b5\u6d88\u5728 CST\u3002<\/section>\n


        \n<\/section>\n
          \n
        • \n

          \n\t\t\tCranial & Spinal Technologies\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 11.65 \u4ebf\u7f8e\u5143\uff0c\u636e\u62a5\u9053\u4e0b\u964d 2%\uff0c\u6709\u673a\u4e0b\u964d 1%\u3002Spine & Biologics \u540c\u6bd4\u6301\u5e73\uff0cCore Spine \u7684\u4f4e\u4e2a\u4f4d\u6570\u589e\u957f\u88ab Biologics \u7684\u4f4e\u4e2a\u4f4d\u6570\u4e0b\u964d\u6240\u62b5\u6d88\u3002\u795e\u7ecf\u5916\u79d1\u4ee5\u4f4e\u4e2a\u4f4d\u6570\u589e\u957f\uff0c\u673a\u5668\u4eba\u6280\u672f\u5728 20 \u5e74\u4ee3\u4e2d\u671f\u589e\u957f\uff0c\u5bfc\u822a\u548c\u52a8\u529b\u624b\u672f\u5668\u68b0\u5728\u5bf9\u8d44\u672c\u8bbe\u5907\u7684\u5f3a\u52b2\u9700\u6c42\u4e0b\u5b9e\u73b0\u9ad8\u4e2a\u4f4d\u6570\u589e\u957f\uff0c\u4f46\u88ab\u6210\u50cf\u548c CSF\uff08\u8111\u810a\u6db2\uff09\u7ba1\u7406\u7684\u4e0b\u964d\u6240\u62b5\u6d88\u4f9b\u5e94\u9650\u5236\u7684\u7ed3\u679c\u3002\n\t\t<\/p>\n

          \n<\/li>\n

        • \n

          \n\t\t\t\u636e\u62a5\u9053\uff0c Specialty Therapies\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 6.84 \u4ebf\u7f8e\u5143\uff0c\u589e\u957f 5%\uff0c\u6709\u673a\u589e\u957f 6%\u3002\u7531\u4e8e\u9752\u5c11\u5e74\u51fa\u8840\u6027\u4e2d\u98ce\u4ea7\u54c1\u7684\u589e\u957f\uff0c\u795e\u7ecf\u8840\u7ba1\u4ee5\u4f4e\u4e24\u4f4d\u6570\u589e\u957f\u3002\u7531\u4e8e\u7ade\u4e89\u52a0\u5267\uff0c\u9aa8\u76c6\u5065\u5eb7\u4e0b\u964d\u4e86\u4e2d\u4e2a\u4f4d\u6570\uff0c\u800c\u7531\u4e8e StealthStation\u2122 \u8033\u9f3b\u5589\u5bfc\u822a\u7cfb\u7edf\u7684\u9500\u552e\u5f3a\u52b2\uff0c\u8033\u9f3b\u5589\u79d1\u589e\u957f\u4e86\u4e2d\u4e2a\u4f4d\u6570\u3002\n\t\t<\/p>\n

          \n<\/li>\n

        • \n

          \n\t\t\t\u636e\u62a5\u9053\uff0c\u795e\u7ecf\u8c03\u8282\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 4.51 \u4ebf\u7f8e\u5143\uff0c\u540c\u6bd4\u6301\u5e73\uff0c\u6709\u673a\u589e\u957f 2%\u3002\u7531\u4e8e Percept\u2122 PC \u6df1\u90e8\u8111\u523a\u6fc0 (DBS) \u7cfb\u7edf\u548c SenSight\u2122 \u5b9a\u5411 DBS \u5bfc\u8054\u7cfb\u7edf\u7684\u6301\u7eed\u91c7\u7528\uff0c\u8111\u8c03\u5236\u589e\u52a0\u4e86\u4f4e\u4e24\u4f4d\u6570\u3002\u75bc\u75db\u6cbb\u7597\u5448\u4f4e\u4e2a\u4f4d\u6570\u4e0b\u964d\uff0c\u9776\u5411\u836f\u7269\u9012\u9001\u7684\u4e2d\u4e2a\u4f4d\u6570\u4e0b\u964d\u90e8\u5206\u88ab\u75bc\u75db\u523a\u6fc0\u7684\u4f4e\u4e2a\u4f4d\u6570\u589e\u957f\u6240\u62b5\u6d88\uff0c\u539f\u56e0\u662f\u7ee7\u7eed\u91c7\u7528 Vanta \u2122\u548c Intellis \u2122\u4e0e DTM \u2122 SCS \u795e\u7ecf\u523a\u6fc0\u5668\u3002\n\t\t<\/p>\n<\/li>\n<\/ul>\n



          \n<\/section>\n
          \u7cd6\u5c3f\u75c5\uff1a23.38 \u4ebf\u7f8e\u5143\uff0c\u4e0b\u964d 3%<\/section>\n
          2022 \u8d22\u5e74\u7cd6\u5c3f\u75c5\u6536\u5165\u4e3a 23.38 \u4ebf\u7f8e\u5143\uff0c\u636e\u62a5\u9053\u548c\u6709\u673a\u6536\u5165\u4e0b\u964d 3%\u3002\u636e\u62a5\u9053\uff0c\u7cd6\u5c3f\u75c5\u7b2c\u56db\u5b63\u5ea6\u6536\u5165\u4e3a 5.97 \u4ebf\u7f8e\u5143\uff0c\u4e0b\u964d 8%\uff0c\u6709\u673a\u4e0b\u964d 5%\u3002\u7531\u4e8e\u7f3a\u4e4f\u65b0\u4ea7\u54c1\u7684\u6279\u51c6\uff0c\u7f8e\u56fd\u7684\u6536\u5165\u5728 20 \u591a\u5c81\u65f6\u6709\u6240\u4e0b\u964d\u3002\u8fd9\u88ab\u975e\u7f8e\u56fd\u53d1\u8fbe\u5e02\u573a\u7684\u4f4e\u4e24\u4f4d\u6570\u6709\u673a\u589e\u957f\u548c\u65b0\u5174\u5e02\u573a\u7684\u9ad8\u9752\u5c11\u5e74\u6709\u673a\u589e\u957f\u6240\u62b5\u6d88\u3002\u56fd\u9645\u9500\u552e\u53d7\u5230\u8010\u7528\u80f0\u5c9b\u7d20\u6cf5\u7684\u4e2d\u4e2a\u4f4d\u6570\u6709\u673a\u589e\u957f\u3001\u6d88\u8017\u54c1\u7684\u4e2d\u4f4d\u6570\u6709\u673a\u589e\u957f\u4ee5\u53ca\u8fde\u7eed\u8840\u7cd6\u76d1\u6d4b (CGM) \u4ea7\u54c1\u7684\u4f4e 20 \u5c81\u6709\u673a\u589e\u957f\u63a8\u52a8\u3002<\/section>\n


          \n<\/section>\n
          \u7f8e\u6566\u529b\u9884\u8ba1\u5176 2023 \u8d22\u5e74\u7684\u6709\u673a\u6536\u5165\u589e\u957f\u5c06\u5728 4%\u81f3 5%\u4e4b\u95f4\u3002\u5982\u679c\u8fd1\u671f\u5916\u6c47\u6c47\u7387\u4fdd\u6301\u4e0d\u53d8\uff0c2023 \u8d22\u5e74\u7684\u6536\u5165\u5c06\u53d7\u5230\u7ea610\u4ebf\u81f311\u4ebf\u7f8e\u5143\u7684\u8d1f\u9762\u5f71\u54cd\u3002

          \n<\/section>\n


          \n<\/section>\n

          \n\t\u201c\u6211\u4eec\u9884\u8ba1\u6700\u8fd1\u548c\u5373\u5c06\u63a8\u51fa\u7684\u4ea7\u54c1\u5c06\u5728\u4e0b\u4e00\u4e2a\u8d22\u5e74\u5bf9\u6211\u4eec\u7684\u4e1a\u52a1\u4ea7\u751f\u5f71\u54cd\uff0c\u201d\u7f8e\u6566\u529b\u9996\u5e2d\u8d22\u52a1\u5b98Karen Parkhill\u8bf4\u3002\u201c\u9884\u8ba1\u4f9b\u5e94\u94fe\u3001\u901a\u8d27\u81a8\u80c0\u548c\u5916\u6c47\u5c06\u9020\u6210\u8fd1\u671f\u538b\u529b\u3002\u7136\u800c\uff0c\u6211\u4eec\u4ecd\u4e13\u6ce8\u4e8e\u63a8\u52a8\u6211\u4eec\u7684\u7814\u53d1\u6295\u8d44\uff0c\u4ee5\u52a0\u901f\u6211\u4eec\u7684\u589e\u957f\u5e76\u4e3a\u6211\u4eec\u7684\u80a1\u4e1c\u521b\u9020\u5de8\u5927\u7684\u957f\u671f\u56de\u62a5\u3002\u201d\n<\/p>\n

          \n\t<\/p>\n

          \n\t\u6765\u6e90\uff1a\u601d\u5b87MedTech<\/p>\n","protected":false},"excerpt":{"rendered":"

          [db:\u6458\u8981]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5],"tags":[30],"_links":{"self":[{"href":"https:\/\/unionmedin.com\/index.php?rest_route=\/wp\/v2\/posts\/1843"}],"collection":[{"href":"https:\/\/unionmedin.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/unionmedin.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/unionmedin.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/unionmedin.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1843"}],"version-history":[{"count":0,"href":"https:\/\/unionmedin.com\/index.php?rest_route=\/wp\/v2\/posts\/1843\/revisions"}],"wp:attachment":[{"href":"https:\/\/unionmedin.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/unionmedin.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/unionmedin.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}